FITC标记的磷酸化红细胞生成素受体抗体
产品名称： FITC标记的磷酸化红细胞生成素受体抗体
英文名称： Anti-phospho-EPO Receptor (Tyr485)/FITC
产品编号： HZ-13088R-FITC
产品价格： null
产品产地： 中国/上海
品牌商标： HZbscience
更新时间： 2023-08-17T10:24:20
使用范围： ICC=1:50-200 IF=1:50-200
上海沪震实业有限公司
- 联系人 : 鲍丽雯
- 地址 : 上海市闵行区闵北路88弄1-30号第22幢AQ136室
- 邮编 : 200612
- 所在区域 : 上海
- 电话 : 139****0749
- 传真 : 021-60345367
- 邮箱 : www.shzbio.net
Rabbit Anti-phospho-EPO Receptor (Tyr485)/FITC Conjugated antibody
FITC标记的磷酸化红细胞生成素受体抗体
| 英文名称 | Anti-phospho-EPO Receptor (Tyr485)/FITC |
| 中文名称 | FITC标记的磷酸化红细胞生成素受体抗体 |
| 别 名 | EPO Receptor (phospho Y485); p-EPO Receptor (phospho Y485); EPOR (phospho Y485); p-EPOR (phospho Y485); erythropoietin receptor; EPO R; EPO Receptor; Erythropoietin receptor precursor; EPOR_HUMAN; MGC138358. |
| 规格价格 | 100ul/2980元 购买 大包装/询价 |
| 说 明 书 | 100ul |
| 产品类型 | 磷酸化抗体 |
| 研究领域 | 心血管 免疫学 干细胞 细胞膜受体 G蛋白偶联受体 G蛋白信号 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human, |
| 产品应用 | ICC=1:50-200 IF=1:50-200 not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 55kDa |
| 细胞定位 | 细胞膜 |
| 性 状 | Lyophilized or Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthesised phosphopeptide derived from human EPO Receptor around the phosphorylation site of Tyr485 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 储 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 产品介绍 | background: The erythropoietin receptor (EPOR) is a member of the cytokine receptor family. There are several isoforms including: EPOR-F (full length), EPOR-S (soluble form), and EPOR-T (truncated form). Upon erythropoietin (EPO) binding, the EPOR activates Jak2 tyrosine kinase which activates different intracellular pathways including: Ras/MAP kinase, phosphatidylinositol 3-kinase and STAT transcription factors. The stimulated EPOR appears to have a role in erythroid cell survival. Defects in the EPOR may produce erythroleukemia and familial erythrocytosis. A functional EPOR is found in the cardiovascular system, including endothelial cells and cardiomyocytes, and data suggest that the EPO/EPO receptor system plays an important role in cardiac function. In animal studies, treatment with EPO during ischemia/reperfusion in the heart has been shown to limit the infarct size and the extent of apoptosis. Function: Receptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase. Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling. Subcellular Location: Cell membrane and Secreted. Secreted and located to the cell surface. Tissue Specificity: Erythroid cells and erythroid progenitor cells. Isoform EPOR-F is the most abundant form in EPO-dependent erythroleukemia cells and in late-stage erythroid progenitors. Isoform EPOR-S and isoform EPOR-T are the predominant forms in bone marrow. Isoform EPOR-T is the most abundant from in early-stage erythroid progenitor cells. Post-translational modifications: On EPO stimulation, phosphorylated on C-terminal tyrosine residues by JAK2. The phosphotyrosine motifs are also recruitment sites for several SH2-containing proteins and adapter proteins which mediate cell proliferation. Phosphorylation on Tyr-454 is required for PTPN6 interaction, Tyr-426 for PTPN11. Tyr-426 is also required for SOCS3 binding, but Tyr-454/Tyr-456 motif is the preferred binding site. Ubiquitinated by NOSIP; appears to be either multi-monoubiquitinated or polyubiquitinated. Ubiquitination mediates proliferation and survival of EPO-dependent cells. DISEASE: Defects in EPOR are the cause of erythrocytosis familial type 1 (ECYT1) [MIM:133100]. ECYT1 is an autosomal dominant disorder characterized by increased serum red blood cell mass, elevated hemoglobin and hematocrit, hypersensitivity of erythroid progenitors to erythropoietin, erythropoietin low serum levels, and no increase in platelets nor leukocytes. It has a relatively benign course and does not progress to leukemia. Similarity: Belongs to the type I cytokine receptor family. Type 1 subfamily. Contains 1 fibronectin type-III domain. Database links: Entrez Gene: 2057 Human Entrez Gene: 13857 Mouse Entrez Gene: 24336 Rat Omim: 133171 Human SwissProt: P19235 Human SwissProt: P14753 Mouse SwissProt: Q07303 Rat Unigene: 631624 Human Unigene: 2653 Mouse Unigene: 22394 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications |
促红细胞生成素受体（EPOR）是细胞因子受体家族的成员。有几种异构体包括：EPOR -F（全长）、EPOR-S（可溶形式）和EPOR -T（截断形式）。当促红细胞生成素（EPO）结合时，EPOR激活Jak2酪氨酸激酶，该激酶激活不同的细胞内途径，包括：Ras/MAP激酶、磷脂酰肌醇3-激酶和STAT转录因子。受刺激的EPOR似乎在红系细胞存活中起作用。EPOR中的缺陷可引起红白血病和家族性红细胞增多症。在心血管系统（包括内皮细胞和心肌细胞）中发现功能性EPOR，数据表明EPO/EPO受体系统在心脏功能中起重要作用。在动物研究中，在心脏缺血/再灌注期间使用EPO治疗已显示出限制梗塞大小和凋亡的程度。